Avidity Partners Management LP Karuna Therapeutics, Inc. Transaction History

Avidity Partners Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $13 Million - $25.7 Million	-80,700 Reduced 28.15%	206,000 $65.2 Million
Q3 2023 Nov 14, 2023	SELL	$164.66 - $218.08 $25.6 Million - $33.9 Million	-155,500 Reduced 35.17%	286,700 $48.5 Million
Q2 2023 Aug 14, 2023	BUY	$176.32 - $240.22 $6.77 Million - $9.22 Million	38,400 Added 9.51%	442,200 $95.9 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $16.9 Million - $21.4 Million	104,800 Added 35.05%	403,800 $73.3 Million
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $25.4 Million - $31.4 Million	-132,800 Reduced 30.75%	299,000 $58.8 Million

Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $28.1 Million - $63 Million	227,230 Added 111.08%	431,800 $97.1 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $19.2 Million - $29.3 Million	204,570 New	204,570 $25.9 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.